Comparing 2 hypotheses side-by-side
Compounds that modulate the surface tension and composition of biomolecular condensates could prevent the aberrant mixing of tau, α-synuclein, and TDP-43 within stress granules and other membraneless organelles where cross-seeding occurs. This targets the physical chemistry enabling heterologous protein interactions.
Transglutaminase-2 creates covalent cross-links between lysine and glutamine residues shared across tau, α-synuclein, and TDP-43, stabilizing heterologous aggregates. Selective TG2 inhibitors targeting the cross-seeding-specific substrate sites could disrupt mixed aggregate formation while preserving physiological TG2 functions.
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
| Dimension | Liquid-Liquid Phase Separation | Transglutaminase-2 Cross-Linki |
|---|---|---|
| Mechanistic | 0.600 | 0.750 |
| Evidence | 0.550 | 0.600 |
| Novelty | 0.900 | 0.700 |
| Feasibility | 0.400 | 0.800 |
| Impact | 0.650 | 0.700 |
| Druggability | 0.300 | 0.850 |
| Safety | 0.350 | 0.650 |
| Competition | 0.850 | 0.750 |
| Data | 0.450 | 0.700 |
| Reproducible | 0.400 | 0.750 |
| KG Connect | 0.787 | 0.742 |
No evidence citations yet
No evidence citations yet
4 rounds · quality: 0.95
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
4 rounds · quality: 0.95
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
Curated mechanism pathway diagrams from expert analysis
graph TD
A["Cellular Stress Triggers"]
B["G3BP1 Activation"]
C["Stress Granule Formation"]
D["LLPS Nucleation"]
E["Tau/alpha-synuclein/TDP-43 Recruitment"]
F["Aberrant Protein Co-aggregation"]
G["Cross-seeding Events"]
H["Pathological Condensate Maturation"]
I["Neuronal Dysfunction"]
J["Synaptic Loss"]
K["Neurodegeneration"]
L["LLPS Modifier Compounds"]
M["Condensate Property Modulation"]
N["Restored Protein Dynamics"]
O["Neuroprotective Outcome"]
P["FUS/hnRNPA1 Co-factors"]
A -->|"oxidative/proteotoxic"| B
B -->|"RNA binding"| C
C -->|"phase transition"| D
D -->|"aberrant recruitment"| E
P -->|"co-assembly"| E
E -->|"pathological mixing"| F
F -->|"prion-like propagation"| G
G -->|"condensate aging"| H
H -->|"cellular toxicity"| I
I -->|"connectivity loss"| J
J -->|"progressive damage"| K
L -->|"therapeutic intervention"| M
M -->|"restored fluidity"| N
N -->|"prevention of aggregation"| E
N -->|"neuroprotection"| O
classDef mechanism fill:#4fc3f7
classDef pathology fill:#ef5350
classDef therapy fill:#81c784
classDef outcome fill:#ffd54f
classDef genetics fill:#ce93d8
class A,D,E,F mechanism
class G,H,I,J,K pathology
class L,M,N therapy
class O outcome
class B,C,P genetics
graph TD
A["""Neuroinflammation
& Calcium Dysregulation"""] -->|"Ca2+ Influx"| B["TG2 Activation
(Transglutaminase-2)"]
B -->|"Isopeptide Bond
Formation"| C["Tau Cross-Linking
& Aggregation"]
B -->|"Protein Cross-Linking"| D["Abeta Oligomer
Stabilization"]
B -->|"ECM Cross-Linking"| E["BBB Disruption
& Matrix Stiffening"]
B -->|"NF-kappaB Activation"| F["Pro-inflammatory
Cytokine Cascade"]
C --> G["Neurofibrillary
Tangle Formation"]
D --> H["Amyloid Plaque
Stabilization"]
E --> I["Peripheral Immune
Cell Infiltration"]
F --> J["Chronic
Neuroinflammation"]
G --> K["Neuronal Death
& Cognitive Decline"]
H --> K
I --> J
J --> K
L["""TG2 Inhibitor
Therapy"""] -->|"Selective Active-Site
Blockade"| M["TG2 Cross-Linking
Inhibition"]
M -->|"Reduced Tau
Cross-Linking"| N["Prevented Tangle
Formation"]
M -->|"Reduced Abeta
Stabilization"| O["Enhanced Abeta
Clearance"]
M -->|"Preserved BBB
Integrity"| P["Reduced Immune
Infiltration"]
M -->|"Suppressed NF-kappaB"| Q["Reduced
Neuroinflammation"]
N --> R["Neuroprotection &
Cognitive Preservation"]
O --> R
P --> R
Q --> R
style A fill:#ff8a80,stroke:#d32f2f,color:#000
style L fill:#4fc3f7,stroke:#2196f3,color:#000
style R fill:#81c784,stroke:#4caf50,color:#000
style K fill:#ffab91,stroke:#e64a19,color:#000